Neurogene Inc.
NASDAQ:NGNEBiotechnology
+$0.76 today
- Market cap
- $365.03M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
Volume 0.28M
Average 0.16M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Neurogene Inc.
NASDAQ:NGNE
Intrinsic Alpha fair value
Locked
Current Price
$23.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Taysha Gene Therapies, Inc. NASDAQ:TSHA | $1.33B | $4.10 | Not rated | -17.7 | -3.61% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +9.16% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +6.94% |
Design Therapeutics, Inc. NASDAQ:DSGN | $670.46M | $10.47 | Not rated | -10.7 | +29.64% |
Alector, Inc. NASDAQ:ALEC | $378.15M | $2.54 | Not rated | -1.4 | +101.57% |
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | $235.59M | $2.87 | Not rated | -4.6 | -68.90% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -64.49% |
Continue the stock analysis
Jump to another research area for this company.